Prime Computer

Prime Medicine is a leading biotechnology company pioneering "Prime Editing," a versatile and precise gene-editing technology designed to deliver one-time curative therapies. Often described as a "search-and-replace" system for the genome, Prime Editing can correct the vast majority of known disease-causing genetic mutations without requiring double-strand DNA breaks. The company is advancing a broad pipeline of therapeutic programs across multiple organs and tissues, including the liver, lung, and central nervous system. Prime Medicine's lead candidate, PM359, recently received IND clearance for the treatment of Chronic Granulomatous Disease, marking the platform's transition into clinical development. The company's approach aims to address genetic diseases that are currently underserved by traditional CRISPR or base editing technologies.